Benign Conditions

Investigators reported that the treatment-emergent adverse event results showed combination tamsulosin and mirabegron was well-tolerated and had a favorable safety profile.

The Optilume drug-coated balloon catheter system has been approved for use in European patients with urethral strictures.

Julia Beth Finkelstein, MD, MPH, CPPS, and colleagues evaluated the safety and costs associated with telemedicine appointments for pediatric urologic patients.

The drug-coated balloon catheter system is being compared with a sham device in a double-blinded randomized trial.

Minimally invasive water vapor thermal therapy offers rapid improvements in LUTS, QoL, and flow rate that remain durable to 5 years in patients with lower urinary tract symptoms due to benign prostatic hyperplasia.

Retreatment rates were low with both aquablation and transurethral resection of the prostate.

In this interview, Jeffrey Weiss, MD, also describes “most exciting area in nocturia research.”

In this interview with Urology Times® Editorial Consultant Gopal Badlani, MD, Weiss also stresses the importance of a 24-hour voiding diary.

The Soltive Laser System, which uses thulium fiber laser technology, has been shown to generate finer particulate and dusted stones in half the time as a standard holmium yttrium aluminium garnet laser.

Alan W. Shindel, MD, provides an expert summary and analysis of the 2020 AUA Guidelines for Disorders of Ejaculation.

The reduction in urinary urgency incontinence episodes observed was “quite significant,” an investigator said.

The novel oral penem anti-infective compound sulopenem showed stronger clinical activity than ciprofloxacin in patients with uncomplicated urinary tract infections with quinolone resistant pathogens, according to findings from the phase 3 SURE1 trial.

In this interview, Gopal H. Badlani speaks to Jeffrey P. Weiss, MD, regarding how Weiss defines nocturia and separating the symptom from overactive bladder.

The guidelines are an evidence-based clinical reference for the treatment of patients with lower urinary tract symptoms secondary to BPH.

Minimally invasive surgical options took front and center in 2018 when the AUA published its revised guideline on the surgical management of male lower urinary tract symptoms secondary to BPH.

Procedure safest when performed in <60 minutes.

A recent study found that sacral neuromodulation monotherapy was efficacious as a third-line treatment.

Nocturia appears to be highly prevalent in the United States, with almost 30% of all women reporting significant nocturia, according to new data reported at the AUA annual meeting in San Francisco.

 Waking up at night to urinate is by far the most bothersome lower urinary tract symptom. 

Performing green laser enucleation of the prostate with a live audience does not result in more complications, researchers say.

Men with large prostates experience more relief from BPH with treatment by Aquablation therapy (using the AquaBeam System) than with transurethral resection of the prostate, researchers say.

In this interview, Thomas Chi, MD, discusses how he performs PCNL, explains why he uses ultrasound instead of fluoroscopy, and offers advice to urologists looking to gain more experience with the procedure.

Studies show moderate alcohol intake has surprising links to prostate disease.

Other pipeline products discussed in this round-up include agents for metastatic urothelial cancer, clear cell renal cell carcinoma, and stress urinary incontinence.

Also read about expansions to an intermittent catheter line, a new radiofrequency treatment for improving local vaginal circulation, an app for men navigating fertility challenges, and more.